Epidemiology Study - Overview

Glioblastoma Study Objective:

To determine the prevalence and incidence of Glioblastoma among individuals in a defined population. This objective outlines the primary aim of the study, which is to establish the frequency of Glioblastoma within a specific age group and geographic area, while also seeking to understand potential factors contributing to its development. Moreover, the report is having geographic coverage including North America, Europe and rest of the world however customisation can be made in the geographic coverage.

Glioblastoma Study USP:

• This epidemiological study on Glioblastoma stands out due to its comprehensive approach in establishing precise prevalence rates, identifying novel risk factors, and exploring geographical variations in a diverse population.

• By integrating advanced imaging techniques with robust statistical analyses, the study aims to provide actionable insights to identify treatment opportunities, target population, and an overview on public health initiatives aimed at mitigating the impact of Glioblastoma related health problems.

• Through meticulous data collection and rigorous methodology, the study not only contributes to the scientific understanding of Glioblastoma but also serves as a foundation for future research events and healthcare policymaking in addressing this increasing Glioblastoma cases.

Glioblastoma related Study Overview:

The study Defines Glioblastoma as an advanced form of disease. The significance of studying Glioblastoma epidemiology is due to its increasing prevalence in different age populations.

Glioblastoma Study Design:

Population: The target population (e.g., elderly individuals aged 64 years and above) and the sampling method (e.g., random sampling from healthcare registries or population databases)

Data Collection: Detail methods for identifying Glioblastoma cases (e.g., clinical examination, imaging studies) and demographic data (age, sex, ethnicity).

Glioblastoma Epidemiological Parameters:

Prevalence: Prevalence rates considered per 1,000 or 10,000 population.

Incidence: Determine annual incidence rates per 1,000 person-years.

Risk Factors: Analyse associations between Glioblastoma and potential risk factors (e.g., age, genetics).

Geographical Variations: Compare prevalence or incidence rates across different regions or countries.

Glioblastoma study summary:

Glioblastoma study summarizes the prevalence, incidence, possible risk factors, and geographic variations of the Glioblastoma worldwide.

Glioblastoma Disease overview:

Glioblastoma is a malignant type of brain tumor, belonging to glioma tumor group, under subtype of astrocytomas, they are considered grade 4 tumors, made up of abnormal astrocytic cells. It is most common type of primary brain cancer, usually start in frontal lobe and temporal lobe of brain, rarely occurring in stem and spinal cord.

It is classified into primary and secondary GBM. Primary GBM occurs without evidence of previous less malignant precursor, and secondary GBM develops from low grade diffuse astrocytoma or anaplastic astrocytoma.

GBM is most common malignant brain tumor, showing incidence of 3.23 per 100,000 individuals in population. They make up to 54% of all gliomas and 16 % of all primary brain tumors, with annual incidence of 35 million individuals, accounting for male to female ratio 1:6:1. According to 2013, central brain tumor registry of united states, it is reported that the average annual age adjusted incidence rate of GBM is 3.19 per 100,000 individuals. Incidence rate in paediatric population is found to be 0.85 per 100,000. Median survival rate of patients suffering from GBM is less than 15 months.

Various medication drugs available for treatment of glioblastoma includes, Temozolomide, Bevacizumab, Carmustine. Nivolumab, Lomustine. Key market players manufacturing the therapeutics used in glioblastoma treatment includes, Bristol Myers Squibb, Eli Lilly, Incyte, AbbVie, Genentech, Celtic Therapeutics, Amgen, Adaptimmune, Loxo Oncology, Iovance Biotherapeutics, Pfizer, Merck, Roche, Novartis.

Glioblastoma Demographic and Environmental Risk Factors:

Age and sex: Primarily this disease is diagnosed at older age, at median age of 64, and the incidence is seen to be elevated with age peaking at 75 to 84 years and starts dropping down after 85years. Diagnosis age for primary GBM is higher with mean age 55 and median age 64 compared to secondary GBM with mean diagnosis age of 40 years. It is not most common in children. Higher GBM incidence rates are seen in males, about 3.97 compared to females with 2.53 in US. Primary GBM incidence rates are higher in men with male to female ratio of 1:0.33 and secondary GBM is seen to be higher in females with 0.65:1 male to female to ratio. GBM at cerebellar location is more common in young patients of 50 to 56 years, supratentorial location GBM incidence is seen higher in older patients of 62 to 64 years.

Ethnicity: Incidence rates of GBM are highest seen in Whites then in Blacks, age adjusted GBM is 2.5 times more in European Americans, compared to African Americans, mostly more common in non-Hispanics then Hispanics.2.0 times higher incidence is seen in Caucasians compared to Africans and Afro-Americans, and lower incidence was observed in Asians and American Indians.

Risk Factors causing Glioblastoma: Risk factors which can cause GBM are as follows; prior exposure to radiation, reduced susceptibility to allergy, immune factors and immune genes, and some nucleotide polymorphisms, detected by genome-wide association. Certain Other factors linked to GBM risk are high socioeconomic status and a person’s height. However, there is no evidence of GBM link with lifestyle characteristics, such as cigarette smoking, alcohol consumption, drug use, or dietary exposure to nitrous compounds, no consistent of definitive reports have been published regarding the association of GBM with the use of mobile phones.

Major risk factor causing GBM is ionising radiation, recognized risk factor for many cancers. Head Injury Because of the described anecdotal cases of CNS tumors (not just GBM) being diagnosed after head trauma. Certain rare genetic diseases, such as Li-Fraumeni and Lynch syndrome, are associated with gliomas. However, these affect only a small portion of patients with glioblastoma.

Glioblastoma Market Scope:

Drivers: Rising Incidence of Glioblastoma-One of the most significant drivers for the growth of the Glioblastoma Market Industry is the rising incidence of glioblastoma, which has been increasingly observed in various populations globally. As medical science advances, the awareness and detection of glioblastoma are improving, leading to more diagnoses. This increase in reported cases is attributed not only to enhanced diagnostic tools and techniques but also to lifestyle factors, genetic predispositions, and environmental influences that have amplified the risk of developing this aggressive brain tumor. Moreover, as populations age, the prevalence of glioblastoma tends to rise, thereby creating a demand for innovative treatment options within the Glioblastoma Market Industry. The complexity of glioblastomas, characterized by abnormal cell growth and rapid progression, highlights the urgent need for effective therapy, which fuels investments in research and development for novel drugs and therapeutic solutions.

Advancements in Research and Development-The Glioblastoma Market Industry is significantly driven by advancements in research and development. Continuous improvement in technology and scientific understanding has resulted in the development of new therapies and treatment protocols. The collaboration between pharmaceutical companies, research institutions, and universities plays a pivotal role in uncovering novel approaches to target glioblastoma effectively. These advancements not only enhance treatment efficacy but also lead to a broader understanding of glioblastoma biology, providing insights into personalized medicine approaches tailored to individual patients. As research expenditures continue to rise, the landscape for glioblastoma therapeutics is transforming, promising better patient outcomes and driving market expansion.

Government Initiatives and Funding-Another critical driver of the Glioblastoma Market Industry is the increase in government initiatives and funding aimed at combating cancer, particularly aggressive forms like glioblastoma. Many governments worldwide are recognizing the urgent need for improved cancer treatments and are allocating substantial resources to funding research initiatives and support programs for glioblastoma patients. These initiatives include grants for scientific research, support for clinical trials, and public advocacy campaigns to raise awareness about glioblastoma. Enhanced funding not only drives innovation in treatment options but also provides resources for healthcare providers and institutions to improve diagnostic processes, ultimately fostering growth in the Glioblastoma Market Industry.

Restraints: several factors hampering the growth of glioblastoma treatment market include, high cost of treatment options available of glioblastoma, lengthy and strict regulatory cycles causing delay in regulatory approval, in turn causing delay in launching the product in market, and side effects of the therapeutics available for its treatment, are cause certain obstacles in growth of market.